Kazia Therapeutics Ltd ADR (KZIA)
KZIA Stock Price Chart
Explore Kazia Therapeutics Ltd ADR interactive price chart. Choose custom timeframes to analyze KZIA price movements and trends.
KZIA Company Profile
Discover essential business fundamentals and corporate details for Kazia Therapeutics Ltd ADR (KZIA) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Jan 1999
Employees
6.00
CEO
John Friend
Description
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase II trial to treat isocitrate dehydrogenase-mutant glioma, primary central nervous system (CNS) lymphoma, diffuse intrinsic pontine glioma, and brain metastases; and in pre-clinical studies to treat triple-negative breast cancer, as well as for the treatment of atypical rhabdoid/teratoid tumors. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3 that is in Phase I clinical trial to treat advanced solid tumors and ovarian cancer. The company has collaborations with the Australian and New Zealand Children’s Haematology/Oncology Group, Genentech Inc., Global Coalition for Adaptive Research, Vivesto AB, Simcere Pharmaceutical Group Ltd, Evotec SE, Sovargen Co., Ltd, and QIMR Berghofer Medical Research Institute. Kazia Therapeutics Limited was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.
KZIA Financial Timeline
Browse a chronological timeline of Kazia Therapeutics Ltd ADR corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Sept 2026
EPS estimate is -$0.70, while revenue estimate is $139.92k.
Earnings released on 16 Mar 2026
EPS came in at -$0.58 falling short of the estimated -$0.01 by -8.21k%, while revenue for the quarter reached $216.90k .
Earnings released on 30 Jun 2025
EPS came in at -$4.18 falling short of the estimated -$0.01 by -63.97k%, while revenue for the quarter reached $12.87k , beating expectations by +23.18%.
Earnings released on 28 May 2025
EPS came in at -$7.61 surpassing the estimated -$10.76 by +29.29%, while revenue for the quarter reached $13.80k .
Stock split effective on 17 Apr 2025
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 19 Nov 2024
EPS came in at -$20.81 falling short of the estimated -$15.00 by -38.75%, while revenue for the quarter reached $1.65m , beating expectations by +1.55k%.
Stock split effective on 28 Oct 2024
Shares were split 1 : 10 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 27 Mar 2024
EPS came in at -$12.53 , while revenue for the quarter reached $3.40 .
Earnings released on 27 Nov 2023
EPS came in at -$10.02 falling short of the estimated -$1.66 by -504.78%, while revenue for the quarter reached $664.10 .
Earnings released on 9 Mar 2023
EPS came in at -$31.86 falling short of the estimated -$24.65 by -29.27%.
Earnings released on 6 Oct 2022
EPS came in at -$30.53 .
Earnings released on 6 Jan 2022
EPS came in at -$36.25 , while revenue for the quarter reached $7.25k .
Earnings released on 30 Sept 2021
EPS came in at -$5.85 , while revenue for the quarter reached $11.40m .
KZIA Stock Performance
Access detailed KZIA performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
